Epilepsy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Further, for NF-κB p65, MDR1, P-gp and apoptosis-associated protein levels detection, miR-542-3p mimic showed a suppressive effect on these KA-induced protein levels, whereas TLR4 overexpression ameliorated the miR-542-3p-induced these protein levels in KA-treated epilepsy rats.
|
31702493 |
2019 |
Epilepsy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our data provide key signaling steps underlying seizure-induced P-gp up-regulation and suggest that mPGES-1 inhibitors could potentially prevent P-gp up-regulation in epilepsy.-Soldner, E. L. B., Hartz, A. M. S., Akanuma, S.-I., Pekcec, A., Doods, H., Kryscio, R. J., Hosoya, K.-I., Bauer, B. Inhibition of human microsomal PGE2 synthase-1 reduces seizure-induced increases of P-glycoprotein expression and activity at the blood-brain barrier.
|
31638830 |
2019 |
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Neuroinflammation due to high levels of glutamate has been identified as one of the causes of P-gp upregulation, and several studies in animal models of epilepsy suggest that antiinflammatory drugs might prevent P-gp overexpression and, thus, avoid the development of refractory epilepsy.
|
31420290 |
2019 |
Epilepsy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our data support the hypothesis that glutamate signals cPLA2 activation, resulting in overexpression of blood-brain barrier P-gp and BCRP.-Hartz, A. M. S., Rempe, R. G., Soldner, E. L. B., Pekcec, A., Schlichtiger, J., Kryscio, R., Bauer, B. Cytosolic phospholipase A2 is a key regulator of blood-brain barrier function in epilepsy.
|
31661303 |
2019 |
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Increasing evidence supports that the efflux transporters, especially P-glycoprotein (P-gp), have vital roles on drug resistance in epilepsy.
|
31061316 |
2019 |
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Indeed, many genes, including genes encoding drug transporters (ABCB1), drug targets (SCN1A), drug-metabolizing enzymes (CYP2C9, CYP2C19), and human leucocyte antigen (HLA) proteins, may regulate the mechanisms of drug resistance in epilepsy.
|
29804481 |
2018 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association between ABCB1 polymorphisms and response to first-generation antiepileptic drugs in a Tunisian epileptic population.
|
29198163 |
2018 |
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study investigates the effect of the Pgp inhibitor verapamil on the anticonvulsant effect of CBZ and its nanoparticulate formulation in the rat model of isoniazid-induced epilepsy.
|
29751140 |
2018 |
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study aimed to assess whether [<sup>11</sup>C]flumazenil is a P-glycoprotein substrate in humans and to what extent increased P-glycoprotein function in epilepsy may confound interpretation of clinical [<sup>11</sup>C]flumazenil studies used to assess gamma-aminobutyric acid A receptors.
|
26661244 |
2017 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The genetic polymorphism of ABCB1 rs1045642 was found to be associated with normalized OXC concentration and therapeutic efficacy in patients with epilepsy (P<0.05).
|
28837897 |
2017 |
Epilepsy
|
0.600 |
Therapeutic
|
disease |
RGD |
By compared to the epilepsy model group, the P-gp expression was not markedly attenuated by the inhibition of NF-κB activity with PDTC treatment, nevertheless with a decrease of NF-κB expression in this intervention group.
|
28303499 |
2017 |
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Hence, our findings support the combination of flavonoid-type P-gp inhibitors and P-gp substrate antiepileptic drugs as a potential therapeutic strategy for the management of pharmacoresistant epilepsy.
|
28602600 |
2017 |
Epilepsy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Exposing isolated rat brain capillaries to glutamate ex vivo upregulated P-gp expression to levels that were similar to those in capillaries isolated from rats that had status epilepticus or chronic epilepsy.
|
28195743 |
2017 |
Epilepsy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of P-gp and its encoded gene mdr1a/b were significantly up-regulated on the brain of KA-induced chronic epilepsy rats or the epilepsy rats treated with CBZ for 1 week, meanwhile with a high expression of PXR.
|
28303499 |
2017 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Relationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in Epilepsy: updated systematic review and meta-analysis.
|
28202008 |
2017 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.
|
26122019 |
2016 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
C3435T polymorphism of MDR1 gene was analysed by the high resolution melting technique in a group of patients with drug-resistant (n = 106) and drug-responsive epilepsy (n = 67), as well as in non-epileptic children (n = 98) hospitalised at the Department of Neurology, Polish Mother's Memorial Hospital in Lodz.
|
27391700 |
2016 |
Epilepsy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The present study attempted to evaluate association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and P-gp activity with treatment response in patients with epilepsy.
|
25121365 |
2016 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this case-control study, we have investigated the role of ABCB1 rs1045642 and rs2032582 and ABCC2 rs2273697 and rs717620 single nucleotide polymorphisms in antiepileptic drug-resistance in patients with epilepsy.
|
27886333 |
2016 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The association between the non-synonymous polymorphism G2677T/A in the coding region of the ABCB1 gene, and the risk of resistance to anti-epileptic drugs (AEDs) in epilepsy remains controversial.
|
26220385 |
2015 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
ABCB1 gene C3435T polymorphism and drug resistance in epilepsy: evidence based on 8,604 subjects.
|
25799371 |
2015 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Previous studies reported the associations between the ATP-binding cassette sub-family B member 1 (ABCB1, also known as MDR1) polymorphisms and their haplotypes with risk of response to antiepileptic drugs in epilepsy, however, the results were inconclusive.
|
25816099 |
2015 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
rs776746 and rs15524 in the CYP3A5 gene tend to affect CBZ metabolism, and rs2032582, rs10234411 in the ABCB1 gene may contribute to inter-individual variation in CBZ and in CBZ-E transport among patients with epilepsy using CBZ in combination with PHT or PB.
|
26421491 |
2015 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The ABCB1 3435C>T polymorphism and type of epilepsy were associated with response to PB.
|
25846690 |
2015 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These findings rule out the MDR1 c.3435C>T polymorphism having a major role or increasing the risk of drug-resistance suggesting a revision is required to determine the contribution of this polymorphism in predicting drug response in epilepsy.
|
25458099 |
2015 |